In another phase II trial, genistein, an isoflavone that may inactivate Akt and NF-κB and enhance the anti-tumor activity of erlotinib and Gem, showed no clear effect on survival of PDAC patients when added to the chemotherapy [35]. This evidence concerns the gene AKT1 and neoplasm.